Miraj

Miraj Therapeutics is a San Diego-based biotechnology company focused on the discovery and development of first-in-class small molecule therapeutics for the treatment of cancer. Founded by a team of veteran drug developers from Mirati Therapeutics, the company utilizes a proprietary structure-based drug discovery platform to target novel pathways in oncology, including the DNA damage response (DDR) system. Miraj is currently advancing its lead programs through preclinical development, with a primary focus on addressing unmet needs in solid tumors. The company's leadership brings deep expertise in medicinal chemistry and precision medicine to the pursuit of transformative cancer therapies. By focusing on high-value targets like USP1, Miraj aims to develop next-generation treatments that can overcome current limitations in oncology care.